Skip To Main Content
  • Article
  • Source: Campus Sanofi

T1 Edition Junior Study

Edition Junior

Download this clinical summary to read about the benefits of Toujeo® Insulin Glargine 300U/ml in children and adolescents from the age of 6 years in this randomised trial. Edition Junior was a 6 month long, open-label, double arm, parallel group, non-inferiority study in 463 children with T1DM. The aim of the study was to demonstrate non-inferiority of Toujeo® vs insulin glargine 100 U/mL from baseline to Week 26.

Download

Our Products

MAT-IE-2300494 (v1.0) Date of Preparation: June 2024